Skip to main content
Clinical Trials/NCT05970770
NCT05970770
Not yet recruiting
Phase 4

Hypotension Prediction Index Therapy is Non-inferior to Continuous Norepinephrine Infusion for Fetal Wellbeing in the Prevention of Spinal Anesthesia-Induced Hypotension for Cesarean Delivery: a Randomized Controlled Trial

Fondazione Policlinico Universitario Agostino Gemelli IRCCS0 sites150 target enrollmentSeptember 1, 2023

Overview

Phase
Phase 4
Intervention
Hypotension Prediction Index
Conditions
Hypotension During Surgery
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Enrollment
150
Primary Endpoint
Fetal Base excess
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

The goal of this randomized controlled trial is to compare for non inferiority for fetal wellbeing Hypotension Prediction Index - Guided Therapy and Continuous Norepinephrine Infusion in in the Prevention of Spinal Anesthesia-Induced Hypotension for Cesarean Delivery.

The main question it aims to answer are:

• are fetal arterial base excess comparable with the two treatments?

Participants will undergo continuous noninvasive hemodynamic monitoring with advanced Hypotension Prediction Index Researchers will compare with patients receiving continuous norepinephrine infusion and standard blood pressure monitoring with arm cuff.

Detailed Description

In the Hypotension Prediction Index group, patients will be monitored continuously with a noninvasive hemodynamic device. The Hypotension Prediction Index is a number based on al algorithm that predicts impeding hypotension if it is greater than 85. In the treatment group, patients will be treated with norepinephrine boluses if the Hypotension Prediction Index is \>85. In the control group patients will be treated with preventive continuous infusion of norepinephrine and blood pressure will be measured noninvasively every minute. Data about blood pressure and the vasopressive treatment will start concomitantly to the administration of spinal anesthesia and will stop after delivery. blood gas samples will be then collected from the placental umbilical artery to compare fetal arterial base excess as primary outcome for non-inferiority.

Registry
clinicaltrials.gov
Start Date
September 1, 2023
End Date
September 1, 2025
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Eligibility Criteria

Inclusion Criteria

  • Pregnant women between the 36th and the 40th week of gestation undergoing spinal anesthesia for elective caesarian delivery.

Exclusion Criteria

  • preeclampsia;
  • eclampsia;
  • atrial fibrillation and sinus tachycardia;
  • cardiovascular diseases;
  • neuromuscular disease;
  • emergent or urgent cesarean delivery;
  • coagulopathies;
  • contraindications to spinal anesthesia.

Arms & Interventions

Hypotension Prediction Index

Patients will be monitored with Hypotension Prediction Index which will guide vasopressor therapy with boluses of norepinephrine

Intervention: Hypotension Prediction Index

Hypotension Prediction Index

Patients will be monitored with Hypotension Prediction Index which will guide vasopressor therapy with boluses of norepinephrine

Intervention: Norepinephrine

Non Invasive Blood Pressure

Spinal-induced hypotension will be prevented by continuous preventive norepinephrine infusion and blood pressure will be monitored by non invasive arm cuff every minute

Intervention: Norepinephrine

Outcomes

Primary Outcomes

Fetal Base excess

Time Frame: at birth

withdrawn from umbilical fetal artery as index of perioperative metabolic acidosis

Secondary Outcomes

  • Hypertensive episodes(from spinal anesthesia until delivery)
  • Apgar score(at 5 minutes from birth)
  • Hypotensive episodes(from spinal anesthesia until delivery)
  • Total vasopressor dose(from spinal anesthesia until delivery)
  • Fetal arterial pH(at birth)

Similar Trials